Sarepta Therapeutics, Inc. (SRPT) Stock
SRPT Key Statistics
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
CEO: Michael E. Severino. Company website
SRPT — Frequently Asked Questions
What is the SRPT stock price today?
Sarepta Therapeutics, Inc. (SRPT) trades at $16.68, up 1.58% on the day, as of Nov 12, 2026 09:31 UTC.
What is Sarepta Therapeutics, Inc.'s market cap?
Sarepta Therapeutics, Inc. has a market capitalisation of $1.76B, calculated from the live SRPT share price and shares outstanding.
What is the P/E ratio of SRPT?
SRPT has no meaningful price-to-earnings ratio: Sarepta Therapeutics, Inc. lost $1.37 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Sarepta Therapeutics, Inc. make?
Sarepta Therapeutics, Inc. generated revenue of $1.96B over the trailing twelve months, which puts the stock at 0.90 times sales.
What is the 52-week range for SRPT?
SRPT has traded between $14.68 and $24.68 over the past 52 weeks, and the last price is 32.4% below that high.
Is Sarepta Therapeutics, Inc. profitable?
No. Sarepta Therapeutics, Inc. is loss-making, with a net margin of -5.86% over the trailing twelve months.
What is the analyst price target for SRPT?
Wall Street analysts rate SRPT Buy, with an average price target of $21.00, 25.9% above the current price.
What sector is Sarepta Therapeutics, Inc. in?
Sarepta Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Sarepta Therapeutics, Inc.?
Michael E. Severino is the chief executive of Sarepta Therapeutics, Inc., which employs 835 people.
Where can I track SRPT in real time?
QFI Terminal shows SRPT with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See SRPT live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open SRPT in Terminal See plans